Effect of Clopidogrel Premedication in Off-Pump Cardiac Surgery
- 4 April 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 113 (13) , 1667-1674
- https://doi.org/10.1161/circulationaha.105.571828
Abstract
Background— Premedication with clopidogrel has reduced thrombotic complications after percutaneous coronary revascularization procedures. However, because of the enhanced and irreversible platelet inhibition by clopidogrel, patients requiring surgical revascularization have a higher risk of bleeding complications and transfusion requirements. A principal benefit of surgical coronary revascularization without cardiopulmonary bypass is its lower hemorrhagic sequelae. The purpose of this study was to evaluate the effect of preoperative clopidogrel administration in the incidence of hemostatic reexploration, blood product transfusion rates, morbidity, and mortality in patients undergoing off-pump coronary artery bypass graft surgery using a large patient sample and a risk-adjusted approach. Methods and Results— Two hundred eighty-one patients (17.9%) did and 1291 (82.1%) did not receive clopidogrel before their surgery, for a total of 1572 patients undergoing isolated off-pump coronary artery bypass graft surgery between January 2000 and June 2002. Risk-adjusted logistic regression analyses and a matched pair analyses by propensity scores were used to assess the association between clopidogrel administration and reoperation as a result of bleeding, intraoperative and postoperative blood transfusions received, and the need for multiple transfusions. Hemorrhage-related preoperative risk factors identified in the literature and those found significant in a univariate model were used. The clopidogrel group had a higher likelihood of hemostatic reoperations (odds ratio [OR], 5.1; 95% confidence interval [CI], 2.47 to 10.47; P P P =0.02), and platelet (OR, 2.5; 95% CI, 1.77 to 3.66; P P =1.00) were not statistically different. Conclusions— Clopidogrel administration in the cardiology suite increases the risk for hemostatic reoperation and the requirements for blood product transfusions during and after off-pump coronary artery bypass graft surgery.Keywords
This publication has 34 references indexed in Scilit:
- Impact of clopidogrel in coronary artery bypass grafting1European Journal of Cardio-Thoracic Surgery, 2004
- Urgent or Emergent Coronary Revascularization Using Bilateral Internal Thoracic Artery after Previous Clopidogrel Antiplatelet TherapyThe Thoracic and Cardiovascular Surgeon, 2003
- The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular diseaseEuropean Heart Journal, 2000
- Comparative Safety and Tolerability of Clopidogrel and AspirinDrug Safety, 1999
- “Low-Dose” Aprotinin Modifies Hemostasis but Not Proinflammatory Cytokine ReleaseThe Annals of Thoracic Surgery, 1997
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- Minimally invasive coronary artery bypass graftingThe Annals of Thoracic Surgery, 1996
- Clinical and lesion morphologic determinants of coronary angioplasty success and complications: Current experienceJournal of the American College of Cardiology, 1995
- Clopidogrel, A Novel Antiplatelet and Antithrombotic AgentCardiovascular Drug Reviews, 1993
- Hemostasis Changes During Cardiopulmonary Bypass SurgerySeminars in Thrombosis and Hemostasis, 1985